CVKD logo

CVKD
Cadrenal Therapeutics, Inc.

6,988
Mkt Cap
$14.89M
Volume
26.00
52W High
$15.99
52W Low
$4.21
PE Ratio
-0.92
CVKD Fundamentals
Price
$5.19
Prev Close
$5.17
Open
$5.28
50D MA
$5.56
Beta
0.99
Avg. Volume
50,746.21
EPS (Annual)
-$6.64
P/B
7.24
Rev/Employee
$0.00
$9.51
Loading...
Loading...
News
all
press releases
CVKD Stock Retail Sentiment Peaks After FDA Clears Phase 3 Path For Blood Clot Drug
Its late-stage trial targets 120 patients globally, with results aimed at pushing for a potential NDA filing in 2029.
News Placeholder
More News
News Placeholder
Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today?
The company said VLX-1005 targets a high-risk heparin complication with limited treatment options.
News Placeholder
Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of the company's stock in a transaction dated Monday, December 29th. The shares were sold at an average...
News Placeholder
Why the underdog mindset could be your business superpower
You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. What does it take to go from refugee kid to Marine pilot, biotech CEO, and author? On this...
News Placeholder
Cadrenal Therapeutics, Inc.
CVKD: Acquires Factor XIa Inhibitors
News Placeholder
Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million
The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.
<
...
1
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available